SCORE

36

MRSN: Mersana Therapeutics is a Sell


The current rating for MRSN is 36, which is 39% below its historic median rating of 50. This indicates higher risk than normal.


The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.